Biovie Inc Stock Price, News & Analysis

BioVie Inc. (NASDAQ: BIVI) has initiated the treatment of its first patient in a Phase 2 clinical trial (NM201) investigating the effects of NE3107 on Parkinson’s disease. This double-blind placebo-controlled study aims to evaluate safety, tolerability, and pharmacokinetics in 40 patients. NE3107 previously demonstrated promising effects in preclinical studies, improving motor symptoms and reducing L-dopa induced dyskinesia. Results are expected by mid-2022, with the trial being a significant milestone for the company's development pipeline in neurodegenerative diseases.

BioVie Inc. (NASDAQ: BIVI) announced its management team's participation in the LifeSci Partners 11th Annual Corporate Access Event, scheduled for January 5-7, 2022. The panel, titled "Defining Yourself When You Fit Into More Than One Basket," will take place on January 7, 2022, at 10:00 AM ET.

BioVie is focused on developing innovative therapies for advanced liver disease and neurodegenerative disorders. Its key candidates include BIV201 for liver cirrhosis and NE3107 for Alzheimer's, with ongoing trials aimed at addressing significant unmet medical needs.

BioVie Inc. (NASDAQ: BIVI) is launching a campaign with the American Liver Foundation to enhance awareness about liver cirrhosis and its complications, specifically refractory ascites. This initiative coincides with BioVie’s Phase 2b clinical trial of BIV201, a continuous infusion of terlipressin, aimed at treating this condition. Approximately 20,000 Americans suffer from refractory ascites, with a one-year survival rate of only 50%. The trial is being conducted at ten research centers in the U.S., and positive results could lead to a pivotal Phase 3 study commencing in 2022.

BioVie Inc. (NASDAQ: BIVI) announced a new debt facility with Avenue Venture Funds, providing up to $25 million, with an initial funding of $15 million on November 30, 2021. This funding aims to support key clinical milestones in 2022, including top-line data from trials of BIV201 in refractory ascites and NE3107 in Alzheimer’s. The company anticipates initiating a Phase 2 trial of NE3107 for Parkinson's disease and a Phase 3 trial for BIV201 for hepatorenal syndrome-acute kidney injury. This non-dilutive financing positions BioVie to advance innovative therapies for unmet medical needs.

BioVie Inc. (NASDAQ: BIVI) announced a key opinion leader webinar on November 11, 2021, focusing on liver cirrhosis complications and an update on the Phase 2b BIV201 study. The session features experts Michael Porayko and Paolo Angeli, who will discuss the progression of liver cirrhosis and the use of terlipressin for hepatorenal syndrome. BIV201, aimed at treating refractory ascites due to liver cirrhosis, holds Orphan drug and Fast Track designations. Top-line results from the Phase 2 study are expected in mid-2022, with a Phase 3 study planned for HRS-AKI pending FDA authorization.

BioVie Inc. has appointed Dr. Joseph M. Palumbo as its new Chief Medical Officer. Dr. Palumbo, a veteran in the pharma industry, will oversee the development of therapies for neurodegenerative and liver diseases. He will lead clinical programs such as NE3107, targeting Alzheimer's and Parkinson's diseases, and BIV201, aimed at treating complications of liver cirrhosis. His extensive experience in drug development is expected to enhance BioVie’s clinical operations, improving the potential for successful trials.

BioVie (NASDAQ: BIVI) has received FDA authorization to commence a Phase 2 study evaluating NE3107 for its potential pro-motoric effects in Parkinson's disease patients. This double-blind, placebo-controlled trial will involve 40 participants and assess safety, tolerability, and efficacy through established motor ratings. NE3107 demonstrates promise in reducing neuroinflammation and enhancing insulin sensitivity, critical to neurodegenerative diseases. The company anticipates patient enrollment to begin by late 2021 and topline results by mid-2022.

BioVie Inc. (NASDAQ: BIVI) has announced a webinar on October 26, 2021, addressing neuroinflammation and insulin resistance related to Alzheimer's Disease. Key opinion leaders will discuss the inflammatory mechanisms in Alzheimer's, while BioVie management will outline the clinical progress of NE3107, their treatment candidate targeting Alzheimer's. The NM101 Phase III clinical study for NE3107 has begun, with 316 subjects enrolled for this randomized trial aimed at treating mild to moderate Alzheimer's. This initiative marks a significant step in BioVie’s plans for addressing neurodegenerative disorders.

BioVie Inc. (NASDAQ: BIVI) announced its management team's participation at the Cantor Virtual Global Healthcare Conference from September 27-30, 2021. A presentation is scheduled for September 29, 2021, at 11:20 a.m. EST, with a webcast available for investors. BioVie, focused on innovative therapies for neurological and liver diseases, is also progressing its Phase 2 study for its Orphan drug candidate BIV201 and initiating a Phase 3 study for NE3107 in Alzheimer's disease. More details can be found on their website.